Wegovy for perimenopause weight gain: what the evidence actually says

The biggest myth: perimenopause weight gain is just 'eating more'

The most common misconception our prescribers encounter is the idea that weight gained during perimenopause is simply the result of letting habits slip. In reality, declining oestrogen levels alter where the body deposits fat (particularly increasing visceral fat around the abdomen) while also slowing metabolic rate and disrupting sleep in ways that drive appetite upward. The NHS's overview of obesity acknowledges the role of biological and hormonal factors alongside lifestyle, and perimenopause is a clear example of biology working against you.

That context matters for Wegovy. Semaglutide reduces appetite by acting on GLP-1 receptors in the brain and gut, slowing gastric emptying and increasing the feeling of fullness after eating. It does not, however, directly address the hormonal shifts driving fat redistribution. So Wegovy can help with the calorie-regulation side of the equation; it cannot replace falling oestrogen. Some women find that combining HRT with weight management support addresses more of what's happening, a conversation worth having with both a GP and a prescriber.

What is still uncertain: there are no large-scale clinical trials specifically examining semaglutide in perimenopausal women as a distinct group. The STEP 1 trial, published in the New England Journal of Medicine, showed roughly 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose across a broad adult population, but perimenopausal status was not reported as a subgroup. Extrapolating those results directly to this specific situation requires caution.

Who actually qualifies, and why perimenopause alone is not enough

Wegovy's UK licence covers adults with a BMI of 30 or above, or a BMI from 27 alongside at least one weight-related health condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. Perimenopause is not itself listed as a qualifying comorbidity, which sometimes surprises women who feel their weight gain is clearly hormone-driven.

In practice, many perimenopausal women do meet the BMI threshold or have an accompanying condition, hypertension and dyslipidaemia both become more common after the hormonal transition and both appear on the qualifying conditions list. Whether you qualify is determined by your prescriber after a full clinical review, not by the symptom list you present with. Our Wegovy overview sets out the licensed eligibility criteria in more detail.

NICE recommends semaglutide (Wegovy) for use within specialist weight management services, for a maximum of two years, in adults with a BMI of 35 or above alongside at least one weight-related comorbidity, the criteria for NHS access are narrower than for private prescription. NICE technology appraisal TA875 sets out the full NHS recommendation. Private access through a regulated pharmacy like ours follows the licensed SmPC criteria rather than the NICE commissioning threshold, and every case is reviewed individually by a GPhC-registered prescriber.

HRT, contraception and a safety point worth knowing

If you are already taking HRT, or considering it alongside weight management support, tell your prescriber about both. NHS England advises that women on tirzepatide consider transdermal HRT (patches or gels) rather than oral tablets, because semaglutide and tirzepatide slow gastric emptying in ways that can theoretically affect oral medication absorption. The evidence base is stronger for tirzepatide on this point; for semaglutide the picture is less definitive, but the precaution is still worth raising with whoever manages your HRT.

On contraception: perimenopause does not mean infertility has ended, and Wegovy is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. The MHRA advises using contraception while on GLP-1 medicines and for a wash-out period before trying to conceive. If you use oral contraceptive pills, discuss this with your prescriber, a non-oral method may be recommended alongside.

If you want to explore how others are approaching semaglutide and the hormonal changes of this life stage, our page on Wegovy and menopause covers the broader context, and this page addresses effectiveness evidence directly. The NHS England guidance on weight-management injections also addresses HRT and contraception considerations clearly.

What to do next, and who to talk to

If you are in perimenopause and finding that weight management feels different from anything you have dealt with before, that is a reasonable and widely shared experience. You are not imagining it. The question of whether Wegovy is right for you depends on your BMI, your current health conditions, your medication list (including HRT), and your own goals, all of which a prescriber needs to assess properly.

A good starting point is to speak to your GP about the perimenopause side of things: whether HRT might help with symptoms and hormonal fat redistribution. At the same time, if your BMI meets the threshold and you want to explore weight management support through a regulated private pharmacy, a free consultation with our prescribing team can clarify whether you are clinically suitable. You can also read about Wegovy specifically for menopause-related weight loss or look at our full range of treatment options. Our clinical team reviews every consultation personally. If you have questions before you start, the FAQs page covers the most common ones. Finding a legitimate, verifiable supplier matters too, any UK pharmacy offering these medicines should be listed on the GPhC register at pharmacyregulation.org.